Spyre Therapeutics
SYRE
78 hedge funds and large institutions have $286M invested in Spyre Therapeutics in 2021 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 29 increasing their positions, 26 reducing their positions, and 9 closing their positions.
204% more call options, than puts
Call options by funds: $316K | Put options by funds: $104K
12% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 26
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0.11% less ownership
Funds ownership: 3.46% → 3.35% (-0.11%)
7% less funds holding
Funds holding: 84 → 78 (-6)
13% less capital invested
Capital invested by funds: $328M → $286M (-$42.8M)
67% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Suvretta Capital Management
New York
|
+$5.28M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$2.89M |
| 3 |
ACM
Altium Capital Management
New York
|
+$2.49M |
| 4 |
Millennium Management
New York
|
+$1.25M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$976K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$7.49M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$3.92M |
| 3 |
BlackRock
New York
|
-$1.79M |
| 4 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$1.39M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$946K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
Daiwa Securities Group
Tokyo,
Japan
| $1K | – | – | – |
|
|
EI
77
Ellevest Inc
New York
| $1K | +$182 | +1 | +20% |
|
|
AIG
78
American International Group
New York
| $158 | -$26.5K | -146 | -14% |
|
|
DCM
79
Driehaus Capital Management
Chicago,
Illinois
| – | -$1.39M | -7,000 | Closed |
|
80
State of Wisconsin Investment Board
Madison,
Wisconsin
| – | -$478K | -2,412 | Closed |
|
81
Two Sigma Advisers
New York
| – | -$268K | -1,352 | Closed |
|
|
MIM
82
MetLife Investment Management
Whippany,
New Jersey
| – | -$161K | -811 | Closed |
|
83
Two Sigma Investments
New York
| – | -$145K | -733 | Closed |
|
|
MLICM
84
Metropolitan Life Insurance Company (MetLife)
New York
| – | -$95.3K | -482 | Closed |
|
|
EGM
85
Engineers Gate Manager
New York
| – | -$86K | -432 | Closed |
|
86
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$29K | -149 | Closed |
|
|
FIA
87
FNY Investment Advisers
New York
| – | -$11K | -60 | Closed |
|
SYRE Hedge Fund Activity: Q2 2021 in Review
78 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Spyre Therapeutics (SYRE) for Q2 2021, worth a combined $286M — down 13% from $328M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of SYRE and 3 opened new positions — a net loss of 6 holders — while 26 trimmed existing stakes and 29 added.
The largest buyer was Suvretta Capital Management, adding an estimated $5.28M. The largest seller was Point72 Asset Management, cutting an estimated $7.49M.
- 78 institutional investors held Spyre Therapeutics (SYRE) as of Q2 2021, down from 84 in Q1 2021.
- Funds reported $286M of Spyre Therapeutics stock for Q2 2021, down 13% quarter-over-quarter.
- 3 funds opened new Spyre Therapeutics positions in Q2 2021 and 9 closed out, a net change of -6 holders.
- The largest Spyre Therapeutics buyer in Q2 2021 was Suvretta Capital Management, an estimated $5.28M added.
- The largest Spyre Therapeutics seller in Q2 2021 was Point72 Asset Management, an estimated $7.49M sold.
Based on aggregated 13F filings for Q2 2021.